Interleukin 36γ Identifies Psoriasis Among Patients With Erythroderma.
Interleukin 36γ Identifies Psoriasis Among Patients With Erythroderma. Acta Derm Venereol. 2015 Nov 2; Authors: Braegelmann J, D Erme AM, Akmal S, Maier J, Braegelmann C, Wenzel J Abstract is missing (Short communication). PMID: 26524325 [PubMed - as supplied by publisher]
Publication date: Available online 14 November 2019Source: Acta Pharmaceutica Sinica BAuthor(s): Jing Jin, Nina Xue, Yuan Liu, Rong Fu, Mingjin Wang, Ming Ji, Fangfang Lai, Jinping Hu, Xiaojian Wang, Qiong Xiao, Xiaoying Zhang, Dali Yin, Xiaoguang Chen, Shuan RaoAbstractPsoriasis is characterized by abnormal proliferation of keratinocytes, as well as infiltration of immune cells into the dermis and epidermis, causing itchy, scaly and erythematous plaques of skin. The understanding of this chronic inflammatory skin disease remains unclear and all available treatments have their limitations currently. Here, we showed that IM...
Authors: Cui XF, Cui XG, Leng N Abstract Papillary renal cell carcinoma (PRCC) accounts for about 10 percent of all renal cell carcinomas, and the prognosis is poor for people with advanced disease. Interleukin-20 receptor subunit beta (IL20RB) is a single-pass type I membrane protein of the type II cytokine receptor family and is related to the pathogenesis of chronic inflammation and autoimmune diseases, including psoriasis, glaucoma, vitiligo, rheumatoid arthritis, and inflammatory bowel disease. However, little has been reported on IL20RB with respect to cancer, especially in PRCC. Thus, we performed this study...
This study does not provide evidence for an increased skin cancer risk in patients treated with NB-UVB phototherapy. However, we have detected the occurence of 10 cases of solar lentigines. Still, definitive prospective longitudinal studies with a greater number of patients and prolonged follow-up are required to specifically address skin cancer risk in relation to NB-UVB phototherapy.
Conclusions: Although heterogeneity across cohorts may explain some medication utilization differences, ustekinumab was associated with lower discontinuation and greater persistence and adherence. PMID: 31714168 [PubMed - as supplied by publisher]
Conditions: Rheumatoid Arthritis; Psoriatic Arthritis; Crohn's Disease; Axial Spondyloarthritis; Plaque Psoriasis Intervention: Drug: Pharmacokinetics of certolizumab pegol Sponsor: UCB Biopharma S.P.R.L. Not yet recruiting
CONCLUSION: The retrieved trials have deficiencies that make it difficult to reliably evaluate the efficacy, safety, and utility of mAb/FP for children and adolescents with chronic inflammatory diseases. mAb/FP nonetheless represent a treatment option to be considered in case conventional immune-modulating drugs are ineffective. Researcher-initiated, high-quality trials and manufacturer-independent, systematic long-term evaluations of adverse effects (e.g., tumors) are sorely needed. PMID: 31711560 [PubMed - in process]
Conclusions The long-term risks of autoimmune disorders are significantly higher in patients with allergic diseases. Allergic diseases and autoimmune disorders show age- and sex-related clustering patterns.
To the Editor, in a prospective cohort study, Snekvik et al. (2017) observed that obesity doubles the incidence risk for psoriasis. This finding may be attributable to the inflammatory role of adipokines: adipose-tissue associated hormones including resistin, leptin, adiponectin, and others. Resistin induces inflammatory markers, including TNF-alpha and IL-6 (Johnston et al. 2008). Independent associations have been reported between psoriasis, elevated serum resistin levels, and cardiovascular disease (CVD) (Muse et al.
In conclusion, the PEST-bp questionnaire proved to be suitable as a screening tool for PsA in patients with psoriasis. Elevated PEST-bp scores are associated with decreased patient quality of life.
In conclusion, immunogenicity data of biosimilars or biosimilar candidates for TNFα or CD20 inh ibitors were collected in trials that varied in design and procedures for ADAb/nAb detection. In general, immunogenicity parameters of biosimilars are similar to those of their reference products.